# Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

> **NCT04419519** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 81 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Venetoclax monotherapy
- **DRUG:** Venetoclax with anti CD20 monoclonal antibody

## Key facts

- **NCT ID:** NCT04419519
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-13
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419519, "Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04419519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*